ABSTRACT
Background Despite the increasing availability of oral PrEP in Europe, gaps remain in the coverage of HIV prevention strategies at a population level. Long-acting injectable PrEP (LA PrEP) has the potential to help provide greater HIV prevention coverage to increasing proportions of men who have sex with men (MSM) and trans people, communities still disproportionately affected by HIV.
Methods An online cross-sectional survey was conducted across 20 European countries from October 2023 to April 2024. The survey was translated into 22 local and migrant languages. The main aim of the survey was to understand which MSM and trans* people in Europe are interested and intend to use LA-PrEP if it becomes available.
Results A total of 15,458 MSM and trans* individuals participated in the survey. Participants were recruited mainly from gay dating apps and through a social media campaign. Overall, the sample was sexually active (96.4%), engaged in condomless anal intercourse in the past 6 months (83.4%), had more than 10 partners in the past 6 months (57.6%) and was PrEP naïve (51.4%).
Conclusions MSM and trans people in Europe can be engaged effectively to participate in research about LA PrEP.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was partly funded by ViiV Healthcare
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Review Committee Psychology and Neuroscience of Maastricht University granted ethical approval for the study (OZL_262_08_01_2023_S21)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Maastricht University, Faculty of Psychology and Neuroscience, owns the datasets and will manage any third-party requests.
